首都医科大学学报 ›› 2012, Vol. 33 ›› Issue (3): 345-349.doi: 10.3969/j.issn.1006-7795.2012.03.013

• 基础研究 • 上一篇    下一篇

重组人粒细胞巨噬细胞刺激因子栓在大鼠和Beagle犬中的免疫原性

蔡永明1,3, 张春云1,2, 申文晋1,3, 李铭1, 姜凌1, 张宗鹏1,3   

  1. 1. 天津药物研究院天津市新药安全评价研究中心,天津 300301;2. 天津中医药大学研究生院药物分析学专业,天津 300193;3. 天津药物研究院释药技术与药代动力学国家重点实验室,天津 300193
  • 收稿日期:2011-12-26 修回日期:1900-01-01 出版日期:2012-06-21 发布日期:2012-06-21
  • 通讯作者: 张宗鹏

Immunogenicity of recombinant human granulocyte-macrophage colony-stimulating factor suppository in rats and beagle dogs

CAI Yong-ming1,3, ZHANG Chun-yun1,2, SHEN Wen-jin1,3, LI Ming1, JIANG Ling1, ZHANG Zong-peng1,3   

  1. 1. Tianjin Centre for Drug Safety Evaluation and Research, Tianjin Institute of Pharmaceutical Research, Tianjin 300301, China;2. Pharmaceutical Analysis, Graduate College, Tianjin University of Tradtional Chinese Medicine, Tianjin 300193, China;3. State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, Tianjin 300193, China
  • Received:2011-12-26 Revised:1900-01-01 Online:2012-06-21 Published:2012-06-21

摘要: 目的 在大鼠和Beagle犬阴道给予重组人粒细胞巨噬细胞刺激因子(recombinant human granulocyte-macrophage colony-stimulating factor,rhGM-CSF)栓3个月的长期毒性试验中,检测给药后动物血清中是否产生抗rhGM-CSF抗体和抗体的中和活性。方法 SD雌性大鼠设rhGM-CSF栓0(赋形剂对照组)、0.24、0.96和3.84 mg/kg 4个组;Beagle雌性Beagle犬设0(赋形剂对照组)、0.07、0.28和1.12 mg/kg 4个组。每天给药1次,连续3个月,恢复期1个月。间接ELISA法检测动物血清中抗rhGM-CSF的结合抗体,TF-1细胞/MTT比色法检测抗体的中和活性。结果 1 大鼠从给药1个月起至恢复期结束,3个剂量组动物血清中均能检测到抗rhGM-CSF的抗体;低剂量和中剂量2组间动物血清的抗体滴度差异无统计学意义,但与高剂量组相比低剂量组和中剂量组差异有统计学意义。体外测活法显示,各剂量组在给药1个月后有部分动物产生中和抗体;给药3个月或恢复期1个月时全部受检动物均产生中和抗体。2 Beagle犬的各剂量组动物血清中均未检测到抗rhGM-CSF的抗体。结论 rhGM-CSF栓经阴道局部连续给予3个月的长期毒性试验中,啮齿类动物大鼠血清中各剂量组均产生抗rhGM-CSF的抗体,且抗体可中和GM-CSF的生物活性;而非啮齿类动物Beagle犬血清中则未检测到抗rhGM-CSF抗体。rhGM-CSF栓对大鼠具有免疫原性。

关键词: 重组人粒细胞巨噬细胞刺激因子栓, 免疫原性, 大鼠, Beagle犬

Abstract: Objective To investigate the anti-recombinant human granulocyte-macrophage colony-stimulating factor (anti-rhGM-CSF) antibody formation and neutralizing antibody activity of rhGM-CSF suppository in repeated-dose toxicity studies in rats and Beagle dogs. Methods The rats received vaginal suppository of rhGM-CSF at doses of 0 (placebo), 0.24, 0.96 and 3.84 mg/kg and Beagle dogs at a dose of 0 (placebo), 0.07, 0.28 and 1.12 mg/kg (daily dosing for up to 3 months), respectively. The titer of anti-rhGM-CSF antibody in serum was measured using indirect enzyme-linked immunosorbent assay (ELISA) and the neutralizing antibodies were determined by an in vitro bioassay. Results Antibodies to rhGM-CSF were detected in all the rats treated with rhGM-CSF suppository during the treatment and recovery period, and neutralizing antibodies were found in serum samples which developed binding antibodies. No anti-rhGM-CSF antibodies were observed in dogs during the experiment of all groups. Conclusion The rats serum contained rhGM-CSF binding antibodies which neutralized the biological activity of rhGM-CSF. Antibodies to rhGM-CSF were not detected in the Beagle dogs serum.

Key words: recombinant human granulocyte-macrophage colony-stimulating factor suppository, immunogenicity, rats, Beagle dogs

中图分类号: